Our delivery system is designed based on the previous work on doxorubicin26,31 exploiting an extremely long circulation time of an albumin as a drug-carrier, but also includes a drug-release mechanism based on the properties of an active PSA at the tumour target site. This evidence concerns the gene KLK3 and neoplasm.